NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Applied Therapeutics, Inc. (APLT) Stock Analysis

Applied Therapeutics, Inc. (APLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

APLT

$0.10

$0.00 (0.00%)

Last trade February 4, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APLT with… →

APLT Key Statistics

As of Feb 4, 2026
Trading
Open
$0.10
Previous Close
$0.10
52-Week Range
0.09–1.50
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.08
Valuation
Market Cap
$14.86M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.86
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.10
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−81.61%
Dividend and dates
Avg Volume
16.03M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APLT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+3.00%
2025−85.27%

As of February 4, 2026.

APLT Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPLTBiotechnology medianvs median
P/S ratio14.8615.263% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Applied Therapeutics, Inc. (APLT) carries a market capitalisation of $14.86M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 28.

The most recent close on file for APLT is $0.10, dated February 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.09 to $1.50. The latest close sits 14.44% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $1.00M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.1.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 14.86. On price-to-sales that is 2.62% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 2.08. Daily returns over the trailing 1 year annualize to a volatility of 194.39%. Over the trailing twelve months the price has returned −81.61%.

Growth & Income

No dividend is on file for APLT.

The record holds one complete calendar year, 2025, which returned −85.27%. So far in 2026 the price is +3.00%.

Peer Comparison

Applied Therapeutics, Inc. (APLT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Applied Therapeutics, Inc. APLT $14.86M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Applied Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of February 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited.

Visit website →